Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 2,594 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,594 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $101.95, for a total value of $264,458.30. Following the sale, the senior vice president directly owned 5,835 shares in the company, valued at $594,878.25. This trade represents a 30.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mirum Pharmaceuticals Trading Up 5.0%

Shares of NASDAQ MIRM traded up $5.09 during mid-day trading on Thursday, hitting $107.13. 1,576,815 shares of the company traded hands, compared to its average volume of 902,868. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 1 year low of $47.89 and a 1 year high of $114.99. The stock has a market capitalization of $6.53 billion, a price-to-earnings ratio of -7.87 and a beta of 0.50. The business has a 50 day moving average of $98.29 and a two-hundred day moving average of $91.88.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) EPS. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the topic of several analyst reports. Leerink Partners dropped their target price on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Stifel Nicolaus set a $136.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. TD Cowen raised their price objective on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, June 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $139.80.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $32,000. Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth $33,000. Finally, Comerica Bank raised its holdings in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.